AllDocs -> cancers

Copyright © 1998 by W.B. Saunders Company. All rights reserved. 342 A BASIC INFORMATION DESCRIPTION A malignant growth in the ovary that is likely to spread to other body parts and threaten life. It affects females of all ages but is most common after age 50. There are many dif- ferent types of ovarian cancer . Epithelial tumors account for the majority and are the most aggressive. Other ovarian cancers are slow growing or metastasized from other can- cers in the body. FREQUENT SIGNS AND SYMPTOMS Frequently no symptoms occur until the tumor becomes large. The earliest symptoms include: • Vague discomfort in the lower abdomen. • Gastrointestinal upsets. • Irregular menstrual periods. Later symptoms: • Deep voice. • Excessive hair growth. • Unexplained weight loss. • An enlarged, hard and sometimes tender mass in the ...

Corporate Medical Policy Oophorectomy, Prophylactic for Ovarian Cancer File Name: oophorectomy_prophylactic_for_ovarian_cancer Policy Number: SUR6480 Origination: 11/1995 Last Review: 8/2003 Next Review: 8/2005 Active policy, no longer scheduled for routine literature review. Description of Procedure or Service Prophylactic oophorectomy is the surgical removal of both ovaries to prevent the development of ovarian cancer in women who are at high risk for the disease. Policy Active policy, no longer scheduled for routine literature review. BCBSNC will provide coverage for Oophorectomy, Prophylactic for Ovarian Cancer when it is deter- mined to be medically necessary because the medical criteria and guidelines shown below are met. Benefits Application Please refer to certificate for availability of benefits. ...

Induction of ovulation and ovarian cancer : a critical review of the literature Ali Mahdavi, M.D., a Tanja Pejovic, M.D., b and Farr Nezhat, M.D. a a Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Science, Mount Sinai School of Medicine, New York, New York; and b Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon Objective: To critically examine the possible association between ovulation-inducing drugs and ovarian cancer . Design: Medline literature review and cross-reference of published data. Results(s): The studies that have adjusted for the effects of confounding factors such as duration of oral contraceptive use and number of pregnancies have noted an increased risk of ovarian cancer among infertile ...

NMT B B R R I I E E F F S S New Medical Therapies Ovarian Cancer O varian cancer originates in tissue exclusive to the ovary, including sur- face epithelial cells, germ cells and the sex cord-stromal cells. Most epithelial ovarian tumors are benign, including serous adeno- mas, mucinous adenomas and Brenner tumors. Malignant epithelial ovarian carcino- mas comprise 85%-90% of all ovarian cancer . Ovarian cancer accounts for 4% of all female cancers, making it the fifth most common cancer among women, except for non-melanoma skin cancers, and the fourth ranked cause of cancer deaths. Although the incidence of ovarian cancer has decreased since 1991, there will be about 25,580 new cases of ovarian cancer and about 16,090 deaths from ovarian cancer in the U.S. during 2004, ...

ovarian cancer 1581 Prevention of Ovarian Cancer Roberta B. Ness , M.D., M.P.H., Chair of the Department of Epidemiology, University of Pittsburgh, Graduate School of Public Health What Puts Women at Risk? Family history of ovarian and breast cancers Infertility Endometriosis Talc use Hormone replacement therapy Does Anything Prevent Ovarian Cancer ? Oral contraceptives Pregnancies Breast feeding (long duration) Tubal ligation Oophorectomy and hysterectomy Controversies NSAIDS Fertility drugs Androgens Diet: fat, coffee Ovarian Cancer Risk and Protection ...

ovarian cancer Ovarian Cancer Zachary B. Self, M3 Incidence/Prevalence: ~25,000 new cases diagnosed annually in U.S. #5 cancer in US women, #3 gyn cancer Most common cause of cancer death from gynecologic tumors in the United States. 1-2% lifetime risk (general population). 15-54% lifetime risk of ovarian cancer for women with a deleterious mutation in BRCA1 or BRCA2 gene. BRCA1 & BRCA2 Mutations: Associated with early onset of breast or ovarian cancer . Inheritance follows an AUTOSOMAL DOMINANT transmission. It can be inherited from either parent. Most cases are related to the BRCA1 gene mutation. BRCA1 is a TUMOR SUPPRESSOR GENE that inhibits cell growth when functioning properly. The inheritance ...

Gene therapy for breast, ovarian cancer A novel gene therapy technique may one day hold out promise for women with breast or ovarian cancer . Naoto T. Ueno of the University of Texas M.D. Anderson Cancer Center in Houston and his colleagues knew that 20 to 30 percent of ovarian and breast cancer patients have a gene, called HER-2/neu, that is hyperactive. They also knew that women with this overactive gene tend to have a poor therapeutic outlook. “The cancer is aggressive,” Ueno says. The team wanted to see if it could slow the cancer by countering the action of HER-2/neu in cancer cells. To do that, the researchers turned to another gene, E1A, which is thought to work by turning off HER-2/neu. They had previously used the E1A gene to treat mice with ovarian cancer . The Texas team recruited 12 people with advanced ovarian or breast cancer . Each recruit received weekly injections ...

FY02 Ovarian Cancer Research Program Peer Reviewers Bai, Wenlong Ph.D. Baron, Andre T. Ph.D. Biochemistry and Molecular Biology, Mayo Clinic Foundation Batra, Surinder K. Ph.D. Dept. of Biochemistry and Molecular Biology, Univ of Nebraska Medical Ctr., Eppley Cancer Ctr Beck, William T. Ph.D. Department of Biopharmaceutical Sciences, University of Illinois at Chicago Benbrook, Doris M. Ph.D. Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center Bieberich, Charles J. Ph.D. Department of Biological Sciences, University of Maryland Baltimore County Bigbee, William L. Ph.D. Cancer Epidemiology Program, University of Pittsburgh Cancer Institute Blay, Jonathan Ph.D. Dept of Pharmacology, Dalhousie University Faculty of Medicine Bouhassira, Eric E. Ph.D. ...